PER, CTX-M, TEM and SHV Beta-lactamases in Clinical Isolates of Klebsiella pneumoniae Isolated from Tehran, Iran

Document Type : Original Article


Department of Microbiology, Pasteur Institute of Iran, Tehran, Iran


Different types of extended spectrum beta-lactamases (ESBLs) are encountered in the clinical settings worldwide. There are a few studies regarding the prevalence of ESBL genes among Klebsiella pneumoniae isolates at Tehran especially those of blaPER and blaCTX. The aim of this study was to determine the prevalence of blaSHV, blaTEM ,blaPER and blaCTX genes among clinical K. pneumoniae of different hospitals in Tehran.
Materials and Methods
Two hundred isolates of K. pneumoniae were received from different clinical specimens. The susceptibility of the isolates to 10 different antibiotics was examined by disk diffusion test. The MICs for ceftazidime were also determined using micro-broth dilution assay. Isolates showing MIC> 4 gg/ml for ceftazidime were screened for ESBL production by phenotypic confirmatory test (PCT) and subjected to PCR for studied genes. Variation among four amplified genes was evaluated using PCR-RFLP.
By disk diffusion test, resistance to ceftazidime and cefotaxime were 34.7% and 33.5% respectively. However, all strains were susceptible to imipenem. Eighty isolates showed MICs> 4 gg/ml for ceftazidime of which 77 (96%) were positive for ESBL in PCT. The prevalence of blaSHV, blaCTX_M, blaTEM and blaPER among these isolates were 26%, 24.5%, '8% and 7.5%, respectively. No variation was detected in the genes by PCR-RFLP.
As far as we know this is the first report of the blaPER-I in K. pneumoniae in Iran. The blaCTX_M was the second most common gene detected among the ESBL positive isolates of K. pneumoniae. For rapid identification of ESBL producing isolates it was recommended that clinical laboratories adopt simple test based on CLSI recommendation for confirming ESBL production in enterobacterial species.


1.Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan JE JR, Gaynes RP. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998; 19:388-394.
2.Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11:589-603.
3.Iroha IR, Egwu OA, Ngozi AT, Chidiebube NA, Chika EP.Extended spectrum beta-lactamase (ESBL) mediated resistance to antibiotics among Klebsiella pneumoniae in enugu Metropolis. Maced J Med Sci 2009; 2:196-199.
4.Paterson DL, Ko WC, Von Gottberg A, Mohapatra S, Casellas JM, Goossens H et al. Implications of extended- spectrum beta-lactamase production in nosocomial infections international prospective study of Klebsiella pneumoniae bacteremia. Ann Intern Med 2004; 140:26-32.
5.Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M P-Lactamases produced by Escherchia coli and Klebsiella spp. J Clin Microbiol 2004; 42:5715-21.
6.Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases.: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
7.Shahcheraghi F, Moezi H, Feizabadi MM. Distribution of TEM and SHV Beta-lactamase genes among Klebsiella pneumoniae strains isolated from patients in Tehran. Med Sci Monit 2007; 13:247-250.
8.Feizabadi MM, Etemadi G, Yadegarinia D, Rahmati M, Shabanpoor S, Bokaei S. Antibiotic-resistance patterns and frequency of extended-spectrum beta-lactamase-producing isolates of Klebsiella pneumoniae in Tehran. Med Sci Monit 2006; 12: BR362-5.
9.Aminzadeh Z,Sadat Kashi M, Sha'bani M. Bacteriuria by extended-spectrum Beta-lactamase producing Escherichia coli and Klebsiella pneumoniae: isolates in a governmental hospital in South of Tehran, Iran. Iran J Kidney Dis 2008; 2:197-200.
10.Ramazanzadeh R, Chitsaz M, Bahmani N. Prevalence and antimicrobial susceptibility of extended-spectrum beta-lactamase-producing bacteria in intensive care units of Sanandaj general hospitals (Kurdistan, Iran). Chemotherapy 2009; 55:287-292.
11.Bazzaz BS, Naderinasab M, Mohamadpoor AH, Farshadzadeh Z, Ahmadi S, Yousefi F. The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiol Immunol Hung 2009; 56:89-99.
12.Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, et al. Distribution of bla(TEM), bla(SHV), bla(CTX-M) genes among clinical isolates of Klebsiella pneumoniae at Labbafinejad hospital, Tehran, Iran. Microb Drug Resist 2010 Mar;16:49-53.
13.Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens:epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998; 11:589-603.
14.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. 5th ed. Approved Standard M2-A8. NCCLS, Villanova: PA, USA: 2004.
15.National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5thed. Approved document M7-A5. Wayne, PA, USA, 2000.
16.National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing.15th informational supplement (M100-s15) NCCLS.
17.Johnson A, Woodford N. Plasmid analysis. In: Johnson A, Woodford P, eitords. Molecular bacteriology protocols and clinical application. London: Human Press; 1998.p.24-28.
18.Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum P-lactamases in a university hospital. J Med Microbiol 1998; 47:201-209.
19.Mendes C, Kiffer C, Segura A, Ribeiro J, Turner P. Klebsiella pneumoniae with multiple antimicrobial resistances. Braz J Infect Dis 2004; 8:109-111.
20.Putman M, VanVeen HW, Konings WN.Molecular properties of bacterial multidrug transporters. Microbial Mol Biol Rev 2000; 64:672-693.
21.Silva1 N, Oliveira M, Bandeira1 AC, Brites C. Risk factors for infection by extended-spectrum beta-lactamase producing Klebsiella pneumoniae in a Tertiary hospital in Salvador, Brazil. Braz J Infect Dis 2006; 10:191-193.
22.Jeong SH, Bae IK, Lee JH, Sohn SG ,Kang GH, Jeon GJ, et al. Molecular characterization of extended- spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey. J Clin Microbiol 2004; 42:2902-2906.
23.Lal P, Kapil A, Das BK, Sood S. Occurrence of TEM and SHV gene in extended spectrum beta-lactamases (ESBLs) producing Klebsiella sp. isolated from a tertiary care hospital. Indian J Med Res 2007; 125:173-8. 
24.Ta§li H, Bahar IH. Molecular characterization of TEM- and SHV-derived extended-spectrum beta-lactamases in hospital-based enterobacteriaceae in Turkey. Jpn J Infect Dis 2005; 58:162-167.
25.Pages JM, Lavigne JP, Leflon-Guibout V, Marcon E, Bert F, Noussair L, et al. Efflux pump, the masked side of B-Lactam resistance in Klebsiella pneumoniae clinical isolates. PLoS One 2009; 4:e4817.
26.Ananthan S, Subha A. Cefoxitin resistance mediated by loss of a porin inclinical strains of Klebsiella pneumoniae and Escherichia coli. Indian J Med Microbiol 2005; 23:20-23.
27.Nathisuwan S,Burgess DS.Extended-spectrum beta-lactamases: epidemiology,detection, and treatment. Pharmacotherapy 2001; 21:920-928.
28.Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-1294.
29.Olson AB, Silverman M, Boyd DA, McGeer A, Willey BM, Pong-Porter V, et al. Identification of a progenitor of the CTX-M-9 group of extended-spectrum beta-lactamases from Kluyvera georgiana isolated in Guyana. Antimicrob Agents Chemother 2005; 49:2112-2115.
30.Bernard H, Tancrede C, Livrelli V, Morand A, Barthelemy M, Labia R. A novel plasmid-mediated extended-spectrum beta-lactamase not derived from TEM- or SHV-type enzymes. J Antimicrob Chemother 1992; 29:590-592.
31.Paterson DL, Ko WC Von Gottberg A, Mohapatra S, Casellas JM, Goossens H Mulazimoglu ,et al. International praspective study of Klebsiella pneumoniae in nosocomial bacteremia:implications of extended- specterum-beta lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
32.Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. Extended-spectrum beta- lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases International Klebsiella Study Group. Antimicrob Agents Chemother 2003; 47:3554-3560.
33.Livermore DM, Hawkey PM, CTX-M: Changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56:451-4.
34.Luzzaro F, Mezzatesta M, Mugnaioli C, Perilli M, Stefani S, Amicosante G, et al. Trends in production of extended-spectrum p-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol 2006; 44:1659-1664.
35.Ahmed AM, Nakano H, Shimamoto T. The first characterization of extended-spectrum B-lactamase-producing Salmonella in Japan. J Antimicrob Chemother 2004; 54:283-284.
36.Weldhagen GF, Poirel L, Nordmann P. Ambler class A extended-spectrum p-lactamases in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2003; 47:2385-2392.